EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Talazoparib engages innate immune activation via PARP trapping–dependent cGAS/STING activation in Ewing Sarcoma

Marianna Carrabotta, Maria Cristina Manara, Lorena Landuzzi, Elisa Simonetti, Andrea Nesca, Evelin Pellegrini, Margherita Maioli, Sofia Avnet, Francesca Ruzzi, Francesca Salamanna, Marco Gambarotti, Pier-Luigi Lollini und 1 weitere

Cancer Letters · 2026-10 · 657 · 218704

DOI: 10.1016/j.canlet.2026.218704 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2026-10. Verfasst von Marianna Carrabotta und 12 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Oncology Research and Functional Genomics (ONCOGEN), IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy. Electronic address: marianna.ca…. Hauptthemen laut MEDLINE: Phthalazines, Sarcoma, Ewing, Nucleotidyltransferases, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Università di Bologna, AIRC Foundation for Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ewing sarcoma (EwS) shows a limited clinical response to poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi), despite promising preclinical data. In this study, we compared five PARPi with different PARP-trapping capacities in PDX-derived cell lines and mouse models. Talazoparib, the strongest PARP-trapping agent, showed markedly greater efficacy than olaparib or veliparib. It triggered extensive DNA damage, micronuclei formation, and activation of the cyclic GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) pathway, leading to robust type I interferon and pro-inflammatory cytokine release, an effect not seen in osteosarcoma. In vivo, talazoparib also reshaped the tumor microenvironment, increasing macrophage infiltration and reducing tumor growth. In vitro, conditioned media from treated EwS cells promoted M0-like macrophage polarization towards an inflammatory M1-like status. These immunostimulatory effects were initiated by tumor-derived interferons and were absent in talazoparib-resistant and olaparib-treated EwS cells, underscoring the importance of the PARP trapping activity of PARPi rather than catalytic inhibition. Combination of talazoparib with exogenous 2'-3'-cyclic GMP-AMP (cGAMP) does not further increase phagocytosis of EwS cells when co-cultured with macrophages, and no additive effects were observed under the tested conditions. Thus, talazoparib is a potent cytotoxic agent with innate immune activation/macrophage-mediated effects, prompting further clinical evaluation in this tumor type.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhthalazinesSarcoma, EwingNucleotidyltransferasesPoly(ADP-ribose) Polymerase InhibitorsImmunity, InnateMembrane ProteinsBone NeoplasmsHumansAnimalscGAS-STING Signaling PathwaySTING ProteinCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseMiceCell Line, TumorMacrophagesTumor MicroenvironmentXenograft Model Antitumor AssaysPiperazinesPoly(ADP-ribose) PolymerasesSignal Transduction

Stichwörter der Autor:innen

Ewing sarcomaImmune responsePARP inhibitors resistanceTalazoparibcGAS/STING pathway

Substanzen

PhthalazinesNucleotidyltransferasestalazoparibPoly(ADP-ribose) Polymerase InhibitorsSTING ProteinCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthasecGAS protein, humanMembrane ProteinsSTING1 protein, humanPiperazines

Autor:innen und Institutionen

  • Laboratory of Oncology Research and Functional Genomics (ONCOGEN), IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy. Electronic address: marianna.carrabotta@ior.it.
  • Laboratory of Oncology Research and Functional Genomics (ONCOGEN), IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
  • Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
  • Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
  • Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
  • Surgical Sciences and Technologies, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.

Förderung

  • Università di Bologna
  • AIRC Foundation for Cancer Research

Zitieren

APA

Carrabotta, M., Manara, M. C., Landuzzi, L., Simonetti, E., Nesca, A., Pellegrini, E., Maioli, M., Avnet, S., Ruzzi, F., Salamanna, F., Gambarotti, M., Lollini, P. L., & Scotlandi, K. (2026). Talazoparib engages innate immune activation via PARP trapping–dependent cGAS/STING activation in Ewing Sarcoma. Cancer Letters, 657, 218704. https://doi.org/10.1016/j.canlet.2026.218704

Vancouver

Carrabotta M, Manara MC, Landuzzi L, Simonetti E, Nesca A, Pellegrini E, et al. Talazoparib engages innate immune activation via PARP trapping–dependent cGAS/STING activation in Ewing Sarcoma. Cancer Letters. 2026;657:218704. doi:10.1016/j.canlet.2026.218704

BibTeX
@article{Carrabotta2026,
  author = {Carrabotta, Marianna and Manara, Maria Cristina and Landuzzi, Lorena and Simonetti, Elisa and Nesca, Andrea and Pellegrini, Evelin and Maioli, Margherita and Avnet, Sofia and Ruzzi, Francesca and Salamanna, Francesca and Gambarotti, Marco and Lollini, Pier-Luigi and Scotlandi, Katia},
  title = {Talazoparib engages innate immune activation via PARP trapping–dependent cGAS/STING activation in Ewing Sarcoma},
  journal = {Cancer Letters},
  year = {2026},
  volume = {657},
  pages = {218704},
  doi = {10.1016/j.canlet.2026.218704}
}
Kostenlos starten →